智通财经网·2026-01-15 07:06Group 1 - The CEO of GPCR, Raymond Stevens, expressed concerns about the influx of generic versions of their experimental weight loss drug, which has not yet been approved [1] - Following the launch of weight loss injections by Eli Lilly and Novo Nordisk, patients turned to generics due to supply shortages, although these shortages have since ended [1] - The CEO of Novo Nordisk indicated that up to 1.5 million patients in the U.S. are using compounded weight loss drugs, highlighting the ongoing issue of generics in the market [1] Group 2 - Pharmaceutical companies claim that the FDA has not done enough to prevent the spread of generics, with a recent statement indicating plans to publish a list of overseas suppliers that meet FDA standards [2] - Compounding pharmacies utilize these raw materials to produce their own branded generic versions of drugs like Wegovy and Zepbound [2] Group 3 - Stevens noted that GPCR's aleniglipron is a small molecule drug with a more complex manufacturing process, making it harder to replicate compared to peptide drugs like Zepbound and Wegovy from Eli Lilly and Novo Nordisk [1]